Angiogenesis inhibitors
AssigneeSanten Pharmaceutical Co., Ltd.
InventorsShiro Mita, Hidehito Matsuoka
Life of this patent
Estimating the term…
Abstract
A method for inhibiting angiogenesis comprising administering to a patient (mammal, such as a human) in need thereof, a pharmaceutically effective amount of an angiogenesis inhibitor containing a compound of formula (I) or a pharmaceutically acceptable salt thereof, either alone or in combination with a pharmaceutically acceptable carrier. The method of treatment may be used to treat diseases in which the angiogenesis participates, particularly retinal diseases such as diabetic retinopathy, macular degeneration, retinal vein occlusion and retinal artery occlusion, neovascular glaucoma and tumors such as hemangioma.
Claims9
A method for treating retinal disease comprising adminstering to a patient in need thereof a pharmaceutically effective amount of a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof, either alone or in combination with a pharmaceutically acceptable carrier,
- wherein R1 and R2 are the same or different, and are hydrogen, lower alkyl, lower alkanoyl, phenylcarbonyl, phenyl-lower alkyl or phenyl-lower alkoxycarbonyl;
- R3 and R4 are the same or different, and are hydroxy, lower alkoxy, amino or lower alkylamino;
- A1, A2 and A3 are the same or different, and are straight-chain or branched lower alkylene;
- and
- m is 0 or 1.
Dependencies are inferred from the claim text.